arrow
J

Joaquı́n Arribas

vall d’hebron institute of oncology
H指数:61
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

作者更正:化疗的疗效受限于表达PD-L2的肿瘤内衰老细胞

2026-05-290
OAAI
Estrogen receptor signaling drives immune evasion and immunotherapy resistance in HR* breast cancer

雌激素受体信号驱动HR+乳腺癌中的免疫逃逸和免疫治疗耐药性

2026-01-161
OA
LOXL2-mediated chromatin compaction is required to maintain the oncogenic properties of triple-negative breast cancer cells
2024-03-071
PRE
The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

表达PD-L2的肿瘤内衰老细胞限制了化疗的功效

2024-01-2424
OAAI
Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer

三阴性乳腺癌中BRD4S,LOXL2和MED1之间的相互作用驱动细胞周期转录

2023-11-083
OAAI
Early-Stage Breast Cancer Detection in Breast Milk
2023-09-1411
OAAI
Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2+breast cancer

PI3K δ 保留抑制剂MEN1611在PIK3CA突变,曲妥珠单抗耐药的HER2乳腺癌中的抗肿瘤活性

2023-03-136
OAAI
ctDNA IN BREAST MILK FOR EARLY DETECTION OF PREGNANCY ASSOCIATED BREAST CANCER
2023-03-010
PRE
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer (September, 10.1038/s41467-022-32828-6, 2022)

高p16表达和杂合RB1丢失是ER乳腺癌中CDK4/6抑制剂抗性的生物标志物 (9月,10.1038/s41467-022-32828-6,2022)

2022-11-140
OAAI
Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer
2022-10-1218
OAAI
Gasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation
2022-09-2620
OAAI
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

高p16表达和杂合RB1缺失是ER乳腺癌中CDK4/6抑制剂耐药的生物标志物

2022-09-0747
OAAI